Announcements Trials
Browse Landscape

Phase

Phase 2 33Phase 1/2 15Phase 1 11Phase NA 7Phase 3 4Phase 2/3 4Phase EARLY_PHASE1 2

Status

Completed 5Terminated 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1CNS 1

Conditions

Neoplasm Metastasis 1Multiple Myeloma 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 7Cyclophosphamide 6pembrolizumab 5Radiosurgery 5Nivolumab 4Fluorouracil 4Carboplatin 4Blood Specimen Collection 4Biopsy 4X-Rays 3Vincristine 3Surveys and Questionnaires 3Proflavine 3Positron-Emission Tomography 3Metformin 3Cisplatin 3Bevacizumab 3fludarabine phosphate 2durvalumab 2atezolizumab 2Varenicline 2Topotecan 2Taxes 2Specimen Handling 2Rituximab 2Radiotherapy 2Positron Emission Tomography Computed Tomography 2Oxaliplatin 2Leucovorin 2Letrozole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Terminated × Granulocyte Colony-Stimulating Factor × Clear all
NCT02774291 2023-08-04

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

Albert Einstein College of Medicine

Phase EARLY_PHASE1 Terminated
3 enrolled 6 charts
CNS

Brain Neoplasms, Neoplasm Metastasis

NCT01537861 2015-01-26

Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

Washington University School of Medicine

Phase EARLY_PHASE1 Terminated
7 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡